• 简

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    How Certara’s NVIDIA AI Partnership Could Reshape CERT’s Long-Term Drug Development Narrative

    Simply Wall St·07/20/2026 14:18:30
    语音播报
    • In July 2026, Certara, Inc. announced a partnership with NVIDIA Corporation to integrate NVIDIA’s BioNeMo Agent Toolkit into Certara’s open, AI-first biosimulation platform, combining scientific software, regulatory expertise, and proprietary datasets with agentic AI to support drug development workflows.
    • This collaboration effectively embeds NVIDIA’s life sciences AI stack inside Certara’s ecosystem, allowing specialized AI agents to interrogate biosimulation models, clinical datasets, and regulatory evidence to accelerate scientifically grounded insight generation while keeping human experts in control.
    • We’ll now explore how integrating NVIDIA’s BioNeMo Agent Toolkit into Certara’s AI-enabled platform could influence the company’s long-term investment narrative.

    Find 48 companies with promising cash flow potential yet trading below their fair value.

    Certara Investment Narrative Recap

    To own Certara, you have to believe that biosimulation and AI enabled model informed drug development become core infrastructure for pharma, and that Certara can convert that position into sustainable software and services revenue. The NVIDIA BioNeMo integration directly reinforces the AI first platform story but does not yet change the near term tension between rising R&D spend and the need to improve profitability, or the key risk that pharma budgets and adoption cycles remain slower than expected.

    Among recent developments, the March 2026 acceptance of Certara’s PBPK modeling predictions by the FDA for the Scemblix NDA is especially relevant. It underlines that regulators are willing to rely on Certara’s biosimulation in high stakes submissions, which is important context as the company layers NVIDIA’s agentic AI on top of its models. Together, regulatory traction and richer AI tooling form a credible catalyst for deeper customer engagement, even as short term bookings and spending efficiency remain under scrutiny.

    Yet against this promising AI story, investors should be aware that...

    Read the full narrative on Certara (it's free!)

    Certara's narrative projects $436.8 million revenue and $8.2 million earnings by 2029. This requires 1.3% yearly revenue growth and a $23.3 million earnings increase from -$15.1 million today.

    Uncover how Certara's forecasts yield a $7.48 fair value, a 8% upside to its current price.

    Exploring Other Perspectives

    CERT 1-Year Stock Price Chart
    CERT 1-Year Stock Price Chart

    While the NVIDIA partnership could strengthen Certara’s AI platform, the most pessimistic analysts were assuming roughly flat revenue near US$420 million and no profitability by 2029, so their concerns about slow software adoption and muted earnings growth may either ease or intensify as this new AI capability plays out.

    Explore 3 other fair value estimates on Certara - why the stock might be worth 13% less than the current price!

    Reach Your Own Conclusion

    Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

    Searching For A Fresh Perspective?

    These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.